Pfizer is to provide its Ibrance (palbociclib) breast cancer drug, viewed as one of the most important in treating the disease, free of charge to NHS patients whilst it awaits a final decision on cost effectiveness by the UK's National Institute For Health and Clinical Excellence (NICE). NICE rejected the drug, which costs £103,000 ($79,650) for a full course, in draft guidance in February. Approximately 6,000 UK patients could be eligible for the treatment.
Pfizer is to provide its Ibrance (palbociclib) breast cancer drug, viewed as one of the most important in treating the disease, free of charge to NHS patients whilst it awaits a final decision on cost effectiveness by the UK's National Institute For Health and Clinical Excellence (NICE). NICE rejected the drug, which costs £79,650 ($103,000) for a full course, in draft guidance in February. Approximately 6,000 UK patients could be eligible for the treatment.